Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab. Bianco A, Patanella A K, Nociti V, Marti A, Frisullo G, Plantone D, De Fino C, Fetta A, Batocchi A P, Rossini P M, et al. Eur Neurol. 2014 Nov 7; 73(1-2):57-65. Epub 2014 Nov 07. PMID: 25402749. Abstract CommentRecommendBookmarkWatch